NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders.
There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed an integrated drug discovery pipeline to identify and discover drugs for disease-causing ncRNAs.
For many ncRNAs, their function depends on direct interactions with proteins. NextRNA has developed and optimized a high-throughput screening platform to discover RNA-protein interactions and screen for molecules that disrupt these disease-relevant interactions. This platform is a key element in an integrated drug discovery pipeline that combines informatic tools, traditional methods, and novel approaches to develop RNA-directed therapies.
Resalis Therapeutics is a biopharma company focused on the development of antisense oligonucleotide (ASO) therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. Resalis …